Vertex Pharmaceuticals (VX1d)
FRA • Healthcare
February 27, 2026 at 16:30 UTC
Name
CEO
Website
Industry
Year Founded
Employees
Vertex Pharmaceuticals is a biotechnology company that discovers, develops, and supplies therapies for serious diseases addressed by targeted approaches. Research is organized around human biology and validated mechanisms, and programs move from early studies to practice with a focus on clear labeling and safe administration. Manufacturing is built for reproducible output and steady availability once a therapy enters routine care. Medical information and field support help clinicians apply guidance without breaking normal workflow. Regional teams manage access within local frameworks, while global functions keep quality and data safeguards aligned. In the healthcare sector and its partner ecosystem, the company positions itself as a long-term supplier that prioritizes continuity for providers and patients.
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Vertex Pharmaceuticals's Technical Indicators Summary
VX1d is currently exhibiting a neutral technical profile, with trend strength remaining subdued as the ADX hovers in a low range, indicating a lack of directional momentum. Momentum indicators present mixed signals: the RSI and MACD suggest consolidation, while the CCI points to some selling pressure. Price is trading below most short- and medium-term moving averages, including the 10- and 50-day SMAs, which are firmly bearish, yet it remains near the 100-day SMA, reflecting some longer-term support. Volatility remains moderate, supported by a stable ATR, and volume trends show mild accumulation with an improving OBV. The instrument is slightly below both the VWAP and classic pivot level, underscoring a balanced tug-of-war between buyers and sellers. Overall, the technical landscape suggests indecision without a clear directional bias.
| Indicator | Value |
|---|---|
RSI (14) | 40.93 |
Stochastic %K (14, 3, 3) | 10.64 |
CCI (20) | -134.58 |
WPR (14) | -96.14 |
Momentum (10) | -22.50 |
MFI | 47.18 |
MACD Level (12, 26) | 0.24 |
Bollinger Bands | $369.20 - $411.19 |
ATR (14) | $7.24 (1.93%) |
ADX (14) | 15.67 |
OBV | -36,329 |
VWAP | $375.75 |
Classic Pivot Point | $378.23 |
Fibonacci Pivot Point | $378.23 |
Simple Moving Averages | $363.16 - $392.42(5 indicators) |
Exponential Moving Averages | $376.31 - $389.80(5 indicators) |
Get premium market insights delivered directly to your inbox.
The day wrapped with VX1d preserving a mild 1.991% upside gap, closing near 412.40. End-of-day, the peer group was modestly in the green at 0.73%, providing a small boost to sentiment. VX1d preserves a mild upside gap, peers green, boosting sentiment.
Price Change
from €404.35 close
+€8.05
Trading Volume
Below avg (104)
64
vs S&P 500 Today
Strong Outperformance
+8.58%
52-Week Position
Mid-range
60.3%
Updated: February 27, 2026 at 16:12 UTC
Executives File New SEC Form 144 Sales
February 27, 2026